Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma.

Kim CY, Hong CM, Kim DH, Son SH, Jeong SY, Lee SW, Lee J, Ahn BC.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1321-9. doi: 10.1007/s00259-013-2443-6. Epub 2013 May 15.

PMID:
23674211
2.

Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.

Kim CY, Jeong SY, Chong GO, Son SH, Jung JH, Kim DH, Lee SW, Ahn BC, Lee J.

Gynecol Oncol. 2015 Mar;136(3):498-504. doi: 10.1016/j.ygyno.2014.12.032. Epub 2014 Dec 31.

PMID:
25557270
3.

Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.

Jiang C, Zhang X, Jiang M, Zou L, Su M, Kosik RO, Tian R.

Ann Nucl Med. 2015 Jun;29(5):442-51. doi: 10.1007/s12149-015-0964-8. Epub 2015 Mar 24.

PMID:
25801633
4.

Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.

Adams HJ, de Klerk JM, Fijnheer R, Heggelman BG, Dubois SV, Nievelstein RA, Kwee TC.

Eur J Haematol. 2015 Jun;94(6):532-9. doi: 10.1111/ejh.12467. Epub 2015 Mar 13.

PMID:
25311082
5.

Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.

Kim JW, Oh JS, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY.

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1353-61. doi: 10.1007/s00259-015-3051-4. Epub 2015 Jun 12.

PMID:
26067088
6.

Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.

Vu CC, Matthews R, Kim B, Franceschi D, Bilfinger TV, Moore WH.

Nucl Med Commun. 2013 Oct;34(10):959-63. doi: 10.1097/MNM.0b013e32836491a9.

PMID:
23921784
7.

Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy.

Moon SH, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, Park K, Choi JY, Ahn MJ.

Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1005-13. doi: 10.1007/s00259-013-2400-4. Epub 2013 Apr 18.

PMID:
23595109
8.

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.

Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee JH, Lee JD.

J Nucl Med. 2014 Jun;55(6):898-904. doi: 10.2967/jnumed.113.131847. Epub 2014 Apr 7.

9.

Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer.

Liao S, Lan X, Cao G, Yuan H, Zhang Y.

Clin Nucl Med. 2013 Sep;38(9):715-20. doi: 10.1097/RLU.0b013e31829f57fa.

PMID:
23856825
10.

Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.

Khong PL, Huang B, Lee EY, Chan WK, Kwong YL.

J Nucl Med. 2014 Jun;55(6):911-6. doi: 10.2967/jnumed.113.131946. Epub 2014 May 12.

11.

Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Bai B, Huang HQ, Cai QC, Fan W, Wang XX, Zhang X, Lin ZX, Gao Y, Xia YF, Guo Y, Cai QQ, Jiang WQ, Lin TY.

Med Oncol. 2013 Mar;30(1):339. doi: 10.1007/s12032-012-0339-0. Epub 2013 Jan 18.

PMID:
23329306
12.

Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, Bom HS.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):925-35. doi: 10.1007/s00259-011-2059-7. Epub 2012 Jan 21.

PMID:
22270509
13.

Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.

Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8. doi: 10.1007/s00259-013-2530-8. Epub 2013 Aug 16.

PMID:
23948859
14.

Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase.

Chang Y, Fu X, Sun Z, Xie X, Wang R, Li Z, Zhang X, Sheng G, Zhang M.

Sci Rep. 2017 Jan 24;7:41057. doi: 10.1038/srep41057.

15.

The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.

Sun Y, Lu P, Yu L.

Acad Radiol. 2016 May;23(5):605-10. doi: 10.1016/j.acra.2016.01.001. Epub 2016 Feb 4.

PMID:
26853968
16.

Predictive value of pre-therapy (18)F-FDG PET/CT for the outcome of (18)F-FDG PET-guided radiotherapy in patients with head and neck cancer.

Picchio M, Kirienko M, Mapelli P, Dell'Oca I, Villa E, Gallivanone F, Gianolli L, Messa C, Castiglioni I.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):21-31. doi: 10.1007/s00259-013-2528-2. Epub 2013 Aug 29.

PMID:
23990143
17.

Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas.

Roh JL, Kim JS, Kang BC, Cho KJ, Lee SW, Kim SB, Choi SH, Nam SY, Kim SY.

J Surg Oncol. 2014 Dec;110(7):869-75. doi: 10.1002/jso.23729. Epub 2014 Aug 2.

PMID:
25088392
18.

Prognostic value of (18)F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer.

Mayoral M, Fernandez-Martinez A, Vidal L, Fuster D, Aya F, Pavia J, Pons F, Lomeña F, Paredes P.

Rev Esp Med Nucl Imagen Mol. 2016 Mar-Apr;35(2):88-95. doi: 10.1016/j.remn.2015.08.005. Epub 2015 Nov 2.

19.

Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity.

Ryu IS, Kim JS, Roh JL, Cho KJ, Choi SH, Nam SY, Kim SY.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):452-61. doi: 10.1007/s00259-013-2571-z. Epub 2013 Oct 1.

PMID:
24081448
20.

Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.

Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T.

Eur J Radiol. 2012 Dec;81(12):4179-84. doi: 10.1016/j.ejrad.2012.07.009. Epub 2012 Aug 9.

PMID:
22884163

Supplemental Content

Support Center